Pipeline
| Phase 1 | Phase 2a | Phase 2 |
|---|
Arteriovenous Fistula (AVF)
Local administration
Chronic Limb Threatening Ischemia (CLTI)
IV administration
Lead indications
Prevention of Arteriovenous Fistula (AVF) maturation failure
To enable functioning vascular access for life-saving hemodialysis treatment in end-stage kidney disease patients.
Chronic Limb Threatening Ischemia (CLTI)
To prevent amputations and other major adverse cardiovascular events in CLTI patients.
Other thromboinflammatory indications
AVF and CLTI development programs provide a gateway to a wide range of indications where thromboinflammation plays a critical role.
The company’s proprietary therapeutic APAC is a conjugate of two natural compounds: an albumin core covered by unfractionated heparin (UFH) chains. APAC can both prevent and treat vascular injuries associated with thromboinflammation.
Our experimental data show that APAC is able to target vascular injury sites, downregulate thromboinflammation, prevent vascular occlusions and atherosclerosis, and protect the heart and kidneys.
APAC mimics natural heparin proteoglycans, binds at vascular injury sites and allows normal healing. Localised action and limited systemic exposure reduce bleeding risk.
APAC is used in hospitals and can be administered with standard of care. Dosing is flexible, either local (AVF) and/or by intravenous infusion (CLTI).
